BioSpace News Archive

SELLAS Life Sciences Group, Inc. announced that a trial in progress poster for the Phase 3 REGAL study of galinpepimut-S in acute myeloid leukemia will be presented at the American Society of Clinical Oncology Annual Meeting, taking place June 2-6, 2023 in Chicago.

Alaunos Therapeutics, Inc. announced that the Company will present early translational data from the first three patients treated in its ongoing TCR-T Library Phase 1/2 trial at the 2023 American Society of Clinical Oncology Annual Meeting taking place June 2-6, 2023, at the McCormick Place Convention Center in Chicago.

Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, announced updated results from Phase 2 of the RINGSIDE study evaluating AL102 in desmoid tumors.

Relay Therapeutics, Inc. announced complete first-in-human dose escalation data for RLY-4008, an investigational, potent, selective and oral small molecule inhibitor of fibroblast growth factor receptor 2.

Bolt Biotherapeutics, Inc. announced the data from its Phase 1 dose-escalation clinical trial of BDC-1001 that will be presented in a poster session at the American Society of Clinical Oncology 2023 Annual Meeting, being held at McCormick Place in Chicago, Illinois and virtually from June 2-6, 2023.

Terns Pharmaceuticals, Inc. announced that the TERN-701 trial-in-progress abstract is now available on the 2023 American Society of Clinical Oncology Annual Meeting website.

Regeneron Pharmaceuticals, Inc. announced updated data from two Phase 2 expansion dose cohorts evaluating investigational linvoseltamab in patients with heavily pre-treated, relapsed/refractory multiple myeloma.

Regeneron Pharmaceuticals, Inc. announced positive data from three independent cohorts evaluating an investigational combination of LAG-3 inhibitor fianlimab and PD-1 inhibitor Libtayo® in adults with advanced melanoma.

Astellas Pharma Inc. will share new research from across its expanding portfolio of approved and investigational cancer therapies during the 2023 American Society of Clinical Oncology Annual Meeting from June 2-6.

AffyImmune Therapeutics, Inc. announced positive safety and early efficacy results from a Phase 1 study of affinity tuned and trackable AIC100 CAR T cells in ICAM-1 positive relapsed and/or refractory advanced poorly differentiated and anaplastic thyroid cancers, which will be presented at the 2023 American Society of Clinical Oncology Annual Meeting in Chicago, Illinois, on June 5, 2023.